Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis

ClinicalTrials.gov ID: NCT05726396

Public ClinicalTrials.gov record NCT05726396. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 7, 2026, 9:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Immune-related colitis from immune checkpoint inhibitors (ICI) is a common adverse effect causing significant morbidity and impairment of quality of life (QoL). Steroids are the first line of treatment for severe ICI induced Immune- mediated diarrhea and colitis (IMDC). If there is no improvement in 48 to 72 hours, other immunosuppressive agents (infliximab, vedolizumab) are recommended. However, efficacy data supporting the use of immunosuppressives for steroid refractory IMDC is limited by case reports/series. Clinical trials focusing on steroid-refractory colitis are sparse. Novel treatments for IMDC outside of blanket immunosuppression are needed. There is robust evidence to suggest that gut microbial diversity and composition is associated with both ICI efficacy and toxicity. Preliminary studies have shown that pathophysiology of immune mediated colitis may be related to loss of gut microbial diversity. Recently, multiple case series have shown the utility of fecal microbiota transplant for treatment of refractory IMDC providing the proof of concept. This is a pilot randomized placebo controlled study to assess the safety and feasibility of oral restorative microbiota therapy (RMT) in patients with steroid- refractory IMDC.

Study identification

NCT ID
NCT05726396
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
University of Minnesota
Other
Enrollment
20 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 22, 2025
Primary completion
Jan 31, 2027
Completion
Jan 31, 2027
Last update posted
Jun 9, 2026

2025 – 2027

United States locations

U.S. sites
9
U.S. states
1
U.S. cities
9
Facility City State ZIP Site status
Essentia Health St. Joseph's Medical Center Brainerd Minnesota 56401 Recruiting
Essentia Health Deer River Clinic Deer River Minnesota 56636 Recruiting
Essentia Health St. Mary's Detroit Lakes Clinic Detroit Lakes Minnesota 56501 Recruiting
Essentia Health Cancer Center Duluth Minnesota 55805 Recruiting
Essentia Health Fosston Fosston Minnesota 56542 Recruiting
Essentia Health Hibbing Clinic Hibbing Minnesota 55746 Recruiting
University of Minnesota Minneapolis Minnesota 55414 Recruiting
Essentia Health Sandstone Sandstone Minnesota 55072 Recruiting
Essentia Health Virginia Clinic Virginia Minnesota 55792 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05726396, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 9, 2026 · Synced Sep 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05726396 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →